(Q46144659)

English

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Bent Ejlertsen

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

author name string

Katrine L Henriksen

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

Birgitte B Rasmussen

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

Anne E Lykkesfeldt

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

Susanne Møller

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

Henning T Mouridsen

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

Acta Oncologica

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

48

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

522-531

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

Tamoxifen in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

The need for advanced breast cancer treatment guidelines: results of an internet-based survey.

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

The discovery and mechanism of action of letrozole

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

The binding of tamoxifen to oestrogen receptor proteins under equilibrium and non-equilibrium conditions

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1080%2F02841860802676383

21 January 2018

Identifiers

10.1080/02841860802676383

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19173092

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46144659&oldid=2094923334"